共 182 条
[1]
Delmas PD(2005)Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation Osteoporos Int 16 1-5
[2]
Rizzoli R(2005)Assessment of fracture risk Osteoporos Int 16 581-589
[3]
Cooper C(2006)Epidemiology, etiology, and diagnosis of osteoporosis Am J Obstet Gynecol 194 S3-S11
[4]
Reginster JY(1999)Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637-645
[5]
Kanis JA(2006)The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 91 870-877
[6]
Borgstrom F(2001)Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-1441
[7]
de Laet C(2004)Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis Arch Intern Med 164 2024-2030
[8]
Johansson H(2005)Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment J Bone Miner Res 20 1507-1513
[9]
Johnell O(2005)One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis N Engl J Med 353 555-565
[10]
Jonsson B(2000)Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis Osteoporos Int 11 434-442